Other Species / Isoforms
  cPLA2 (human)      LTP 

LTP (Low Throughput Papers) : The number of records in which this modification site was determined using methods other than discovery mass spectrometry.

 HTP 

HTP (High Throughput Papers): The number of records in which this modification site was assigned using ONLY proteomic discovery mass spectrometry.

 
S2-p
______MsFIDPyQH
0 4
cPLA2 (human) ______MsFIDPyQH S2-p
cPLA2 (mouse) ______MsFIDPYQH S2-p
cPLA2 (rat) ______MSFIDPYQH S2
Y7-p
_MsFIDPyQHIIVEH
0 1
cPLA2 (human) _MsFIDPyQHIIVEH Y7-p
cPLA2 (mouse) _MsFIDPYQHIIVEH Y7
cPLA2 (rat) _MSFIDPYQHIIVEH Y7
T21-p
HQYSHKFtVVVLRAT
0 1
cPLA2 (human) HQYSHKFtVVVLRAT T21-p
cPLA2 (mouse) HQYSHKFTVVVLRAT T21
cPLA2 (rat) HQYSHKFTVVVLRAT T21
T31-p
VLRATKVtkGAFGDM
0 1
cPLA2 (human) VLRATKVtkGAFGDM T31-p
cPLA2 (mouse) VLRATKVTKGTFGDM T31
cPLA2 (rat) VLRATKVTKGTFGDM T31
K32-ub
LRATKVtkGAFGDML
0 3
cPLA2 (human) LRATKVtkGAFGDML K32-ub
cPLA2 (mouse) LRATKVTKGTFGDML K32
cPLA2 (rat) LRATKVTKGTFGDML K32
Y96
ITLMDANYVMDETLG
0 1
cPLA2 (human) ITLMDANYVMDETLG Y96
cPLA2 (mouse) ITLMDANyVMDEtLG Y96-p
cPLA2 (rat) ITLMDANYVMDETLG Y96
T101
ANYVMDETLGTATFT
0 1
cPLA2 (human) ANYVMDETLGTATFT T101
cPLA2 (mouse) ANyVMDEtLGtATFP T101-p
cPLA2 (rat) ANYVMDETLGTATFP T101
T104
VMDETLGTATFTVSS
0 1
cPLA2 (human) VMDETLGTATFTVSS T104
cPLA2 (mouse) VMDEtLGtATFPVSS T104-p
cPLA2 (rat) VMDETLGTATFPVSS T104
K155-ub
MALCDQEktFRQQRK
0 2
cPLA2 (human) MALCDQEktFRQQRK K155-ub
cPLA2 (mouse) MALCDQEKtFRQQRK K155
cPLA2 (rat) MALCDQEKTFRRQRK K155
T156-p
ALCDQEktFRQQRKE
0 1
cPLA2 (human) ALCDQEktFRQQRKE T156-p
cPLA2 (mouse) ALCDQEKtFRQQRKE T156-p
cPLA2 (rat) ALCDQEKTFRRQRKE T156
K171-ac
HIRESMKkLLGPkNs
0 2
cPLA2 (human) HIRESMKkLLGPkNs K171-ac
cPLA2 (mouse) NIKENMKkLLGPKKS K171-ac
cPLA2 (rat) NIKENMKKLLGPKKS K171
K176-ac
MKkLLGPkNsEGLHs
0 1
cPLA2 (human) MKkLLGPkNsEGLHs K176-ac
cPLA2 (mouse) MKkLLGPKKSEGLYS K176
cPLA2 (rat) MKKLLGPKKSEGLYS K176
K176-ub
MKkLLGPkNsEGLHs
0 1
cPLA2 (human) MKkLLGPkNsEGLHs K176-ub
cPLA2 (mouse) MKkLLGPKKSEGLYS K176
cPLA2 (rat) MKKLLGPKKSEGLYS K176
S178-p
kLLGPkNsEGLHsAR
0 1
cPLA2 (human) kLLGPkNsEGLHsAR S178-p
cPLA2 (mouse) kLLGPKKSEGLYSTR S178
cPLA2 (rat) KLLGPKKSEGLYSTR S178
S183-p
kNsEGLHsARDVPVV
0 1
cPLA2 (human) kNsEGLHsARDVPVV S183-p
cPLA2 (mouse) KKSEGLYSTRDVPVV S183
cPLA2 (rat) KKSEGLYSTRDVPVV S183
S228-p
ATYVAGLsGSTWYMS
Downstream
4 0
Effects on Modified Protein
  • activity, induced
  • enzymatic activity, induced
cPLA2 (human) ATYVAGLsGSTWYMS S228-p
cPLA2 (mouse) ATYIAGLSGSTWYMS S228
cPLA2 (rat) ATYVAGLsGSTWYMS S228-p
K257-ub
EINEELMkNVSHNPL
0 1
cPLA2 (human) EINEELMkNVSHNPL K257-ub
cPLA2 (mouse) EINEELMKNVSHNPL K257
cPLA2 (rat) EINEELMKNVSHNPL K257
T268-p
HNPLLLLtPQkVkRY
Upstream
0 12
Treatment
  • nocodazole
cPLA2 (human) HNPLLLLtPQkVkRY T268-p
cPLA2 (mouse) HNPLLLLtPQKVKRY T268-p
cPLA2 (rat) HNPLLLLTPQKVKRY T268
K271-ub
LLLLtPQkVkRYVES
0 1
cPLA2 (human) LLLLtPQkVkRYVES K271-ub
cPLA2 (mouse) LLLLtPQKVKRYVES K271
cPLA2 (rat) LLLLTPQKVKRYVES K271
K273-ub
LLtPQkVkRYVESLW
0 1
cPLA2 (human) LLtPQkVkRYVESLW K273-ub
cPLA2 (mouse) LLtPQKVKRYVESLW K273
cPLA2 (rat) LLTPQKVKRYVESLW K273
K281-ub
RYVESLWkKkSSGQP
0 1
cPLA2 (human) RYVESLWkKkSSGQP K281-ub
cPLA2 (mouse) RYVESLWKKKSSGQP K281
cPLA2 (rat) RYVESLWKKKSSGQP K281
K283-ub
VESLWkKkSSGQPVT
0 1
cPLA2 (human) VESLWkKkSSGQPVT K283-ub
cPLA2 (mouse) VESLWKKKSSGQPVT K283
cPLA2 (rat) VESLWKKKSSGQPVT K283
K316-ub
NTTLSSLkEKVNTAQ
0 5
cPLA2 (human) NTTLSSLkEKVNTAQ K316-ub
cPLA2 (mouse) SMTLSSLKEKVNAAR K316
cPLA2 (rat) STTLSSLKEKVSAAR K316
Y359-p
YEIGMAKyGTFMAPD
0 1
cPLA2 (human) YEIGMAKyGTFMAPD Y359-p
cPLA2 (mouse) YEIGMAKYGTFMAPD Y359
cPLA2 (rat) YEIGMAKYGTFMTPD Y359
S370-p
MAPDLFGskFFMGtV
0 1
cPLA2 (human) MAPDLFGskFFMGtV S370-p
cPLA2 (mouse) MAPDLFGSkFFMGTV S370
cPLA2 (rat) MTPDLFGSKFFMGTV S370
K371-ub
APDLFGskFFMGtVV
0 8
cPLA2 (human) APDLFGskFFMGtVV K371-ub
cPLA2 (mouse) APDLFGSkFFMGTVV K371-ub
cPLA2 (rat) TPDLFGSKFFMGTVV K371
T376-p
GskFFMGtVVKKYEE
Upstream
Downstream
1 0
Effects on Modified Protein
  • enzymatic activity, induced
Effects on Biological Processes:
  • carcinogenesis, induced
  • signaling pathway regulation
Putative in vivo kinases:
  • PKCZ (human)
Regulatory protein:
  • PIK3CA (human)
Treatment
  • PKC-zeta_inhibitor
  • serum
cPLA2 (human) GskFFMGtVVKKYEE T376-p
cPLA2 (mouse) under review -
cPLA2 (rat) under review -
S412-p
LGVSGSQsRGSTMEE
0 1
cPLA2 (human) LGVSGSQsRGSTMEE S412-p
cPLA2 (mouse) LGVSGSQNKGSTMEE N412
cPLA2 (rat) LGVSGSQNKGSTMEE N412
S431-p
ITTKHIVsNDssDsD
0 7
cPLA2 (human) ITTKHIVsNDssDsD S431-p
cPLA2 (mouse) ITAKHIVsNDssDsD S431-p
cPLA2 (rat) ITAKHIVSNDssDsD S431
S434-p
KHIVsNDssDsDDEs
0 23
cPLA2 (human) KHIVsNDssDsDDEs S434-p
cPLA2 (mouse) KHIVsNDssDsDDEA S434-p
cPLA2 (rat) KHIVSNDssDsDDEA S434-p
S435-p
HIVsNDssDsDDEsH
0 23
cPLA2 (human) HIVsNDssDsDDEsH S435-p
cPLA2 (mouse) HIVsNDssDsDDEAQ S435-p
cPLA2 (rat) HIVSNDssDsDDEAQ S435-p
S437-p
VsNDssDsDDEsHEP
Upstream
2 52
Treatment
  • EGF
  • thrombin
cPLA2 (human) VsNDssDsDDEsHEP S437-p
cPLA2 (mouse) VsNDssDsDDEAQGP S437-p
cPLA2 (rat) VSNDssDsDDEAQGP S437-p
S441-p
ssDsDDEsHEPKGtE
0 2
cPLA2 (human) ssDsDDEsHEPKGtE S441-p
cPLA2 (mouse) ssDsDDEAQGPKGtE A441
cPLA2 (rat) ssDsDDEAQGPKGTE A441
T447-p
EsHEPKGtENEDAGs
0 2
cPLA2 (human) EsHEPKGtENEDAGs T447-p
cPLA2 (mouse) EAQGPKGtENEEAEK T447-p
cPLA2 (rat) EAQGPKGTENEDAER T447
S454-p
tENEDAGsDyQsDNQ
Upstream
2 5
Treatment
  • collagen
  • SB203580
  • thrombin
cPLA2 (human) tENEDAGsDyQsDNQ S454-p
cPLA2 (mouse) tENEEAEKEyQSDNQ K454
cPLA2 (rat) TENEDAEREYQNDNQ R454
Y456-p
NEDAGsDyQsDNQAs
0 8
cPLA2 (human) NEDAGsDyQsDNQAs Y456-p
cPLA2 (mouse) NEEAEKEyQSDNQAS Y456-p
cPLA2 (rat) NEDAEREYQNDNQAS Y456
S458-p
DAGsDyQsDNQAsWI
0 1
cPLA2 (human) DAGsDyQsDNQAsWI S458-p
cPLA2 (mouse) EAEKEyQSDNQASWV S458
cPLA2 (rat) DAEREYQNDNQASWV N458
S463-p
yQsDNQAsWIHRMIM
0 1
cPLA2 (human) yQsDNQAsWIHRMIM S463-p
cPLA2 (mouse) yQSDNQASWVHRMLM S463
cPLA2 (rat) YQNDNQASWVHRMLM S463
S505-p
LNTSYPLsPLSDFAT
Upstream
Downstream
23 14
cPLA2 (human)
S505-p
cPLA2 (mouse)
S505-p
cPLA2 (rat)
S505-p
Effects on Modified Protein
  • activity, induced
  • enzymatic activity, induced
  • intracellular localization
Effects on Biological Processes:
  • carcinogenesis, induced
  • cell growth, altered
  • cytoskeletal reorganization
  • signaling pathway regulation
Kinase, in vitro:
  • ERK2 (human)
Regulatory protein:
  • ARRB1 (human)
  • ARRB2 (human)
  • cPLA2 (human)
  • DAGLBETA (human)
  • IL17RD (human)
  • IQGAP1 (human)
  • KRas (human)
  • KSR (human)
  • PIK3CA (human)
  • PXN iso2 (human)
  • RAF1 (human)
Treatment
  • 4-DAMP
  • ACh
  • arachidonic_acid
  • arsenite
  • bisindolylmaleimide
  • collagen
  • cycloheximide
  • EGF
  • fMLP
  • IFN-alpha
  • LY294002
  • methoctramine
  • PAA
  • PD98059
  • phorbol_ester
  • PKC-zeta_inhibitor
  • rapamycin
  • Ro31-8220
  • SB203580
  • serum
  • thrombin
  • TNF
  • U0126
  • virus infection
cPLA2 (human) LNTSYPLsPLSDFAT S505-p
cPLA2 (mouse) LNTSYPLsPLRDFss S505-p
cPLA2 (rat) LNTSYPLsPLRDFsP S505-p
A511
LsPLSDFATQDsFDD
0 2
cPLA2 (human) LsPLSDFATQDsFDD A511
cPLA2 (mouse) LsPLRDFssQDsFDD S511-p
cPLA2 (rat) LsPLRDFsPQDsFDD S511-p
T512
sPLSDFATQDsFDDD
0 2
cPLA2 (human) sPLSDFATQDsFDDD T512
cPLA2 (mouse) sPLRDFssQDsFDDE S512-p
cPLA2 (rat) sPLRDFsPQDsFDDD P512
S515-p
SDFATQDsFDDDELD
Upstream
3 6
Kinase, in vitro:
  • CAMK2A (rat)
Putative in vivo kinases:
  • CAMK2A (rat)
Treatment
  • KN-93
  • norepinephrine
cPLA2 (human) SDFATQDsFDDDELD S515-p
cPLA2 (mouse) RDFssQDsFDDELdA S515-p
cPLA2 (rat) RDFsPQDsFDDDELD S515-p
D522
sFDDDELDAAVADPD
0 1
cPLA2 (human) sFDDDELDAAVADPD D522
cPLA2 (mouse) DsFDDELdAAVADPD D521-ca
cPLA2 (rat) sFDDDELDAAVADPD D522
Y535-p
PDEFERIyEPLDVkS
0 33
cPLA2 (human) PDEFERIyEPLDVkS Y535-p
cPLA2 (mouse) PDEFERIyEPLDVKS Y534-p
cPLA2 (rat) PDEFERIYEPLDVKS Y535
K541-ub
IyEPLDVkSKKIHVV
0 4
cPLA2 (human) IyEPLDVkSKKIHVV K541-ub
cPLA2 (mouse) IyEPLDVKSKKIHVV K540
cPLA2 (rat) IYEPLDVKSKKIHVV K541
K541-sm
IyEPLDVkSKKIHVV
0 1
cPLA2 (human) IyEPLDVkSKKIHVV K541-sm
cPLA2 (mouse) IyEPLDVKSKKIHVV K540
cPLA2 (rat) IYEPLDVKSKKIHVV K541
K595-ub
KELLLAEkWAKMNKL
0 1
cPLA2 (human) KELLLAEkWAKMNKL K595-ub
cPLA2 (mouse) KELLLAEKWAKMNKL K594
cPLA2 (rat) KELLLAEKWAKMNKL K595
K606-ub
MNKLPFPkIDPYVFD
0 1
cPLA2 (human) MNKLPFPkIDPYVFD K606-ub
cPLA2 (mouse) MNKLPFPKIDPYVFD K605
cPLA2 (rat) MNKLPFPKIDPYVFD K606
K618-ub
VFDREGLkECYVFKP
0 1
cPLA2 (human) VFDREGLkECYVFKP K618-ub
cPLA2 (mouse) VFDREGLKECYVFKP K617
cPLA2 (rat) VFDREGLKECYVFKP K618
K691
QYPNQAFKRLHDLMH
0 1
cPLA2 (human) QYPNQAFKRLHDLMH K691
cPLA2 (mouse) QYPNQAFkRLHDLMY K690-ac
cPLA2 (rat) QYPNQAFKRLHDLMY K691
K691-ub
QYPNQAFkRLHDLMH
0 1
cPLA2 (human) QYPNQAFkRLHDLMH K691-ub
cPLA2 (mouse) QYPNQAFKRLHDLMY K690
cPLA2 (rat) QYPNQAFKRLHDLMY K691
S715-p
IKEAMVEsIEyRRQN
0 1
cPLA2 (human) IKEAMVEsIEyRRQN S715-p
cPLA2 (mouse) IKDAIVESIEYRRQN S714
cPLA2 (rat) IKDAIVESIEYRRQN S715
Y718-p
AMVEsIEyRRQNPsR
0 1
cPLA2 (human) AMVEsIEyRRQNPsR Y718-p
cPLA2 (mouse) AIVESIEYRRQNPsR Y717
cPLA2 (rat) AIVESIEYRRQNPSR Y718
S724-p
EyRRQNPsRCsVsLS
Upstream
0 4
Treatment
  • BI2536
  • MLN8054
cPLA2 (human) EyRRQNPsRCsVsLS S724-p
cPLA2 (mouse) EYRRQNPsRCsVsLs S723-p
cPLA2 (rat) EYRRQNPSRCsVsLS S724
S727-p
RQNPsRCsVsLSNVE
Upstream
Downstream
8 33
Effects on Modified Protein
  • enzymatic activity, induced
  • intracellular localization
  • molecular association, regulation
Treatment
  • arsenite
  • BI2536
  • collagen
  • IFN-alpha
  • ionomycin
  • okadaic_acid
  • phorbol_ester
  • SB203580
  • thrombin
  • vemurafenib
cPLA2 (human) RQNPsRCsVsLSNVE S727-p
cPLA2 (mouse) RQNPsRCsVsLsNVE S726-p
cPLA2 (rat) RQNPSRCsVsLSNVE S727-p
S729-p
NPsRCsVsLSNVEAR
Upstream
0 32
Treatment
  • anti-CD3
  • AZD1152
  • ischemia
  • ZM447439
cPLA2 (human) NPsRCsVsLSNVEAR S729-p
cPLA2 (mouse) NPsRCsVsLsNVEAR S728-p
cPLA2 (rat) NPSRCsVsLSNVEAR S729-p
S731
sRCsVsLSNVEARRF
0 1
cPLA2 (human) sRCsVsLSNVEARRF S731
cPLA2 (mouse) sRCsVsLsNVEARKF S730-p
cPLA2 (rat) SRCsVsLSNVEARKF S731
K741-ub
EARRFFNkEFLSKPK
0 1
cPLA2 (human) EARRFFNkEFLSKPK K741-ub
cPLA2 (mouse) EARKFFNKEFLSKPT K740
cPLA2 (rat) EARKFFNKEFLSKPT K741
-
gap
0 1
cPLA2 (human) gap -
cPLA2 (mouse) gap -
cPLA2 (rat) LSKPTAEsI______ S751-p